Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Edge Therapeutics discontinues phase III NEWTON 2 study of EG-1962

March 29, 2018

European Commission expands indication for Feraccru

March 28, 2018

Jiangsu Hengrui Medicine Co., Shanghai Hengrui Pharmaceutical Co. patent factor XIa inhibitors

March 27, 2018

Hemlibra approved in Japan

March 27, 2018

EMA committee issues negative opinion on Portola's betrixaban

March 26, 2018

First patient dosed in phase III study of BCX-7353 for HAE

March 16, 2018

Positive topline data from phase III study of ALXN-1210 in patients with PNH

March 16, 2018

Interim ANNEXA-4 data show high rate of hemostasis with andexanet alfa

March 15, 2018

Merck & Co. discovers FXIa and plasma kallikrein inhibitors

March 13, 2018

UCL studies FLT180a gene therapy in patients with hemophilia B

March 13, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...